Anlon Healthcare Intrinsic Value
AHCL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹140.80 | ₹112.64 - ₹168.96 | -1.1% | EPS: ₹6.40, Sector P/E: 22x |
| Book Value Method | asset | ₹40.00 | ₹36.00 - ₹44.00 | -71.9% | Book Value/Share: ₹20.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹74.00 | ₹66.60 - ₹81.40 | -48.0% | Revenue/Share: ₹37.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹87.50 | ₹78.75 - ₹96.25 | -38.6% | EBITDA: ₹35.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹49.59 | ₹44.63 - ₹54.55 | -65.2% | EPS Growth: 9.7%, Fair P/E: 7.7x |
| Growth Adjusted P/E | growth | ₹103.20 | ₹92.88 - ₹113.52 | -27.5% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹80.00 | ₹72.00 - ₹88.00 | -43.8% | ROE: 25.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹42.73 | ₹38.46 - ₹47.00 | -70.0% | EPS: ₹6.40, BVPS: ₹20.00 |
Want to compare with current market value? Check AHCL share price latest .
Valuation Comparison Chart
AHCL Intrinsic Value Analysis
What is the intrinsic value of AHCL?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Anlon Healthcare (AHCL) is ₹80.00 (median value). With the current market price of ₹142.42, this represents a -43.8% variance from our estimated fair value.
The valuation range spans from ₹40.00 to ₹140.80, indicating ₹40.00 - ₹140.80.
Is AHCL undervalued or overvalued?
Based on our multi-method analysis, Anlon Healthcare (AHCL) appears to be trading above calculated value by approximately 43.8%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.88 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 2.26 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 25.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 24.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.82x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Anlon Healthcare
Additional stock information and data for AHCL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-23 Cr | ₹-23 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-3 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹-15 Cr | ₹-17 Cr | Negative Cash Flow | 3/10 |